Latin American Pulmonary Hypertension Registry

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT02570737
• Date of registration: 06/10/2015
• Prospective Registration: No
• Primary sponsor: Asociacion Latinoamericana de Torax
• Public title: Latin American Pulmonary Hypertension Registry RELAHP
• Scientific title: Latin American Pulmonary Hypertension Registry
• Date of first enrolment: April 2014
• Target sample size: 500
• Recruitment status: Enrolling by invitation
• URL: https://clinicaltrials.gov/show/NCT02570737
• Study type: Observational [Patient Registry]
• Phase: N/A

Countries of recruitment

Argentina, Brazil, Chile, Colombia, Honduras, Mexico, Uruguay, Venezuela

Contacts

• Name: TOMAS R. PULIDO, M.D.
• Affiliation: ASOCIACIÓN LATINOAMERICANA DE TORAX

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients at least 18 years old

- Patients with any Group of Pulmonary Hypertension according to OMS Clinical
Clasification (PH by RHC)

- Informed consent

Exclusion Criteria:

- Severe pulmonary function abnormalities (vital capacity < 60% predicted, FEV1 < 50%
predicted)

- Abnormal pulmonary capillary wedge pressure (> 15 mmHg)

- Refusal to participate.

- Patients younger than 18 years old



Age minimum: N/A
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Pulmonary Hypertension

Primary Outcome(s)

Major adverse cardiovascular events [Time Frame: 5 years (Patients will be followed six-monthly for a minimum of five years)]

Secondary Outcome(s)

Cardiovascular death [Time Frame: 5 years]

Secondary ID(s)

Cardioneumology

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Actelion

Bayer

Ferrer Internacional S.A.